Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Minimal Residual Disease (MRD) Status in FCR-Treated CLL Patients at the End of Treatment Influences Progression Free Survival (PFS), Results of the Ctrial-IE (ICORG) 07-01/ CLL Ireland Study, with Mutational Analysis Providing Additional Insight

Niamh Appleby, FRCPath, Fiona M Quinn, PhD, David O'Brien, FAMLs, Smyth Liam, MRCPI, Johanna Kelly, BSc, Imelda Parker, Kathleen Scott, PhD, Mary R Cahill, MB, FRCPath, Gerard Crotty, Helen Enright, MD FRCPI, FRCPath, Brian Hennessy, MD MRCPI, FRCPath, Andrew Hodgson, MBBS, BSc, FRCP, FRCPath, Maeve Leahy, FRCPath, Hilary M O'Leary, FRCPath, Michael E O'Dwyer, MD, Amjad Hayat, MBBS, MRCP, MRCPath, PhD, Elisabeth A. Vandenberghe, MB, MRCPI, MRCPath, PhD

Blood (2016) 128 (22): 3237.

https://doi.org/10.1182/blood.V128.22.3237.3237

Published: 2016

Journal Articles

European Post-Approval Safety Study (PASS) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety, Including SPM, in a Large Cohort of Patients Treated with Lenalidomide, Thalidomide, and Bortezomib

Barbara Gamberi, Miguel Hernandez, Christian Berthou, Eleni Tholouli, Elena Zamagni, Roman Hájek, Monique Minnema, Meletios A Dimopoulos, Jo Caers, Niels Frost Andersen, Bjorn Andreasson, Anders Waage, MD PhD, Gerard Crotty, Elisabeth Kueenburg, Barbara Rosettani, Antonia Di Micco, Pamela Bacon, Igor Blau

Blood (2016) 128 (22): 3331.

https://doi.org/10.1182/blood.V128.22.3331.3331

Published: 2016

Journal Articles

Turning the Heat up a Notch in Biclonal Lymphoproliferative Disorders

Helen Fogarty, Anita Dowling, David O'Brien, Christopher Laurence Bacon, Patrick Thornton, Brian Hennessy, MD MRCPI, FRCPath, Hilary M O'Leary, FRCPath, Gerard Crotty, Robert Henderson, James Nolan, Elisabeth A. Vandenberghe, MB, MRCPI, MRCPath, PhD, Fiona M Quinn, PhD

Blood (2016) 128 (22): 5569.

https://doi.org/10.1182/blood.V128.22.5569.5569

Published: 2016

Journal Articles

A Phase II Multi-Center Study of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RsqVD) in Newly Diagnosed Multiple Myeloma - Ctrial-IE (ICORG) 13-17 Study

Blood (2016) 128 (22): 2117.

https://doi.org/10.1182/blood.V128.22.2117.2117

Published: 2016

Journal Articles

Clinical Characteristics, Treatment and Outcomes for Patients with Myelodysplastic Syndromes and Chromosome 5q Abnormalities in the Republic of Ireland

Su Wai Maung, MBBS, MRCP(UK), Cian McEllistrim, MRCPI, Amjad Hayat, MBBS, MRCP, FRCPath, PhD, Margaret Murray, FRCPath, Michael O'Dwyer, MD, Patrick Thornton, FRCPath, Emma Groarke, MRCPI, Denis O'Keeffe, MD MRCPath, Maeve Leahy, MD MRCPath, Aine Burke, MRCP,MD, Peter O'Gorman, Carmel Weldon, M.Sc, MRCPI, Gerard Crotty, MD FRCPath, Meegahage Ratnakanthi Perera, MDMRCPath,MBBS, Cathie Burke, RN, Johnny McHugh, FRCPath, Helen Enright, MD FRCPI, FRCPath, Ronan Desmond, MD FRCPath

Blood (2015) 126 (23): 5258.

https://doi.org/10.1182/blood.V126.23.5258.5258

Published: 2015

Journal Articles

Minimal Residual Disease Stratification in Fludarabine Ccyclophosphamide Rituximab (FCR) Therapy in Chronic Lymphocytic Leukaemia (CLL

Amjad Hayat, MBBS, PhD, David O'Brien, Fiona Quinn, PhD, Fionnuala Keane, PhD, Imelda Parker, PhD, Johanna Kelly, BSc, Marzena Wieczorkowska, Gerard Crotty, MD, Maeve Leahy, MD, Helen Enright, MD, Brian Hennessy, MD, Mary Cahill, MB, Elisabeth A. Vandenberghe, MB, PhD

Blood (2012) 120 (21): 1791.

https://doi.org/10.1182/blood.V120.21.1791.1791

Published: 2012

NARROW

Minimal Residual Disease (MRD) Status in FCR-Treated CLL Patients at the End of Treatment Influences Progression Free Survival (PFS), Results of the Ctrial-IE (ICORG) 07-01/ CLL Ireland Study, with Mutational Analysis Providing Additional Insight

European Post-Approval Safety Study (PASS) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety, Including SPM, in a Large Cohort of Patients Treated with Lenalidomide, Thalidomide, and Bortezomib

Turning the Heat up a Notch in Biclonal Lymphoproliferative Disorders

A Phase II Multi-Center Study of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RsqVD) in Newly Diagnosed Multiple Myeloma - Ctrial-IE (ICORG) 13-17 Study

Clinical Characteristics, Treatment and Outcomes for Patients with Myelodysplastic Syndromes and Chromosome 5q Abnormalities in the Republic of Ireland

Minimal Residual Disease Stratification in Fludarabine Ccyclophosphamide Rituximab (FCR) Therapy in Chronic Lymphocytic Leukaemia (CLL

Email alerts

ASH Publications

American Society of Hematology

Minimal Residual Disease (MRD) Status in FCR-Treated CLL Patients at the End of Treatment Influences Progression Free Survival (PFS), Results of the Ctrial-IE (ICORG) 07-01/ CLL Ireland Study, with Mutational Analysis Providing Additional Insight

European Post-Approval Safety Study (PASS) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety, Including SPM, in a Large Cohort of Patients Treated with Lenalidomide, Thalidomide, and Bortezomib

Turning the Heat up a Notch in Biclonal Lymphoproliferative Disorders

A Phase II Multi-Center Study of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RsqVD) in Newly Diagnosed Multiple Myeloma - Ctrial-IE (ICORG) 13-17 Study

Clinical Characteristics, Treatment and Outcomes for Patients with Myelodysplastic Syndromes and Chromosome 5q Abnormalities in the Republic of Ireland

Minimal Residual Disease Stratification in Fludarabine Ccyclophosphamide Rituximab (FCR) Therapy in Chronic Lymphocytic Leukaemia (CLL

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only